HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells.

Abstract
BPR0Y007, a bis-benzylidenecyclopentanone derivative (2,5-bis- (4-hydroxy-3-methoxybenzylidene) cyclopentanone), was identified in our laboratory as a novel antineoplastic agent with a broad spectrum of antitumor activity against many human cancer cells. A previous study showed that BPR0Y007 inhibited DNA topoisomerase I (Top 1) activity and prevented tubulin polymerization. Notably, no cross-resistance with BPR0Y007 was observed in camptothecin-, VP-16- or vincristine-resistant cell lines. In this study, we further investigated the cellular and molecular events underlying the antitumoral function of this compound in human oral epidermoid carcinoma KB cells, focusing on the early cytotoxic effect. Treatment of KB cells with BPR0Y007-induced G(2)/M phase arrest followed by sub-G(1) phase accumulation. Annexin-V-propidium iodide (PI) binding assay and DNA fragmentation assay further indicated that BPR0Y007-induced cell death proceeded through an apoptotic pathway as opposed to via necrosis. This compound produced a time-dependent activation of caspases-3 and -8, however, another caspase-3 initiator, caspase-9, was only marginally activated at later time point. We further demonstrated that the activation of the caspases cascade and nuclear fragmentation was not associated with inactivated Bcl-2 and perturbed mitochondrial membrane potential by BPR0Y007. The finding that BPR0Y007-induced apoptosis through a membrane-mediated mechanism was supported by up-regulated expression of Fas (CD95/APO-1), but not Fas-L. Furthermore, up-regulation of p53 and its affected gene, MDM2, in KB cells was found after BPR0Y007 exposure. Overall, our results demonstrated that the BPR0Y007 could induce an early cytotoxic apoptosis through a caspase-8-dependent but mitochondrial-caspase-9 independent pathway, and involving upregulation of p53.
AuthorsShin-Hun Juang, Wen-Yu Pan, Ching-Chuan Kuo, Jing-Ping Liou, Yi-Mei Hung, Li-Tzong Chen, Hsing-Pang Hsieh, Jang-Yang Chang
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 68 Issue 2 Pg. 293-303 (Jul 15 2004) ISSN: 0006-2952 [Print] England
PMID15194001 (Publication Type: Journal Article)
Chemical References
  • 2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone
  • Antineoplastic Agents
  • Benzylidene Compounds
  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • Pentanones
  • Proteins
  • Tumor Suppressor Protein p53
  • fas Receptor
  • CASP3 protein, human
  • CASP8 protein, human
  • CASP9 protein, human
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases
Topics
  • Antineoplastic Agents (pharmacology)
  • Apoptosis
  • Benzylidene Compounds (pharmacology)
  • Carcinoma, Squamous Cell (pathology)
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • Caspases (metabolism)
  • Dose-Response Relationship, Drug
  • Enzyme Activation (drug effects)
  • Fas Ligand Protein
  • G2 Phase (drug effects)
  • Humans
  • KB Cells
  • Membrane Glycoproteins (metabolism)
  • Mitochondria (drug effects, physiology)
  • Mitosis (drug effects)
  • Pentanones (pharmacology)
  • Proteins (metabolism)
  • Time Factors
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 (metabolism)
  • Up-Regulation (drug effects)
  • fas Receptor (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: